For practitioners: This library is organized to support clinical education conversations. All PubMed IDs link to the National Library of Medicine abstract. Full text is available through PubMed Central for open-access articles; others require institutional access or purchase.
Section 1: 3D Spheroid Culture and MSC Biology
-
Bartosh TJ, Ylostalo JH, Mohammadipoor A, et al. Aggregation of human mesenchymal stromal cells (MSCs) into 3D spheroids enhances their antiinflammatory properties. Proceedings of the National Academy of Sciences USA. 2010;107(31):13724-13729.
Seminal PNAS study from Prockop laboratory demonstrating that MSC spheroid aggregation dramatically enhances anti-inflammatory secretome. Showed upregulation of TSG-6, SDF-1, and IL-10 in spheroid versus 2D cultures. Demonstrated that spheroid MSCs suppress macrophage inflammatory response more effectively than 2D MSCs at equivalent cell numbers. Established 3D aggregation as a functional activating step for MSC paracrine biology.
-
Cesarz Z, Tamama K. Spheroid culture of mesenchymal stem cells. Stem Cells International. 2016;2016:9176357.
Comprehensive review of morphological, transcriptomic, metabolic, and paracrine changes in MSC spheroids versus 2D culture. Documented cytoskeletal reorganization from stress fiber-dominated to cortical actin, HIF-1alpha activation in spheroid core, and secretome upregulation across VEGF, HGF, SDF-1, and multiple anti-inflammatory cytokine axes. Provided mechanistic framework for understanding why geometry matters for MSC function.
-
Ylostalo JH, Bartosh TJ, Coble K, Prockop DJ. Human mesenchymal stem/stromal cells cultured as spheroids are self-activated to produce prostaglandin E2 that directs stimulated macrophages into an anti-inflammatory phenotype. Stem Cells. 2012;30(10):2283-2296.
Demonstrated that MSC spheroids spontaneously upregulate COX-2 and prostaglandin E2 (PGE2) production without external inflammatory stimulus — a self-activation of the anti-inflammatory paracrine network that does not occur in 2D culture without inflammatory challenge. Showed spheroid-conditioned media drives M2 macrophage polarization and reduces TNF-alpha, IL-6, and IL-12 production. Direct demonstration of spheroid-specific functional activation.
-
Murphy KC, Whitehead J, Zhou D, Ho SS, Leach JK. Engineering fibrin hydrogels to promote the wound healing potential of mesenchymal stem cell spheroids. Acta Biomaterialia. 2017;64:176-186.
Demonstrated superior angiogenic and wound healing paracrine output from MSC spheroids versus 2D cultures when delivered in fibrin hydrogels. Documented VEGF, bFGF, and SDF-1 upregulation from spheroid cultures and improved endothelial tube formation in co-culture assays. Supports spheroid culture for manufacturing exosome preparations intended for tissue repair applications.
Section 2: Exosome Cargo and Extracellular Vesicle Biology
-
Haraszti RA, Miller R, Stoppato M, et al. Exosomes produced from 3D cultures of MSCs by tangential flow filtration show higher yields and improved activity. Molecular Therapy. 2018;26(12):2838-2847.
Head-to-head comparison of EV yield and activity from 3D spheroid versus 2D monolayer MSC culture using tangential flow filtration isolation. Documented 3-5x higher particle yield per cell from 3D cultures by NTA, and demonstrated superior functional activity of 3D-derived exosomes in Huntington's disease neuronal model assays at matched particle concentrations. Key paper establishing both the yield and the cargo quality advantage of 3D culture for EV manufacturing.
-
Villarroya-Beltri C, Gutierrez-Vazquez C, Sanchez-Cabo F, et al. Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs. Nature Communications. 2013;4:2980.
Identified hnRNPA2B1 as the primary sorting factor for GGAG-motif miRNAs including miR-146a into exosomes. Demonstrated that sumoylation of hnRNPA2B1 (regulated by cellular signaling) controls sorting activity and miRNA loading efficiency. Establishes the mechanism by which cellular signaling state (different in 3D versus 2D MSC culture) determines miRNA packaging into exosomes.
-
Squadrito ML, Baer C, Burdet F, et al. Endogenous RNAs modulate microRNA sorting into extracellular vesicles and transfer to acceptor cells. Cell Reports. 2014;8(5):1432-1446.
Demonstrated active, sequence-specific sorting of miRNAs into EVs mediated by competing endogenous RNA networks and RNA-binding proteins. Showed that EV miRNA content reflects the intracellular RNA regulatory environment — confirming that culture conditions that change RNA-binding protein expression (as 3D vs 2D culture does) will change EV miRNA cargo.
-
Thery C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018). Journal of Extracellular Vesicles. 2018;7(1):1535750.
International Society for Extracellular Vesicles (ISEV) community consensus guidelines defining minimum information required for EV studies. Establishes characterization standards including NTA, tetraspanin surface marker confirmation (CD9, CD63, CD81), negative marker requirements (calnexin negative for ER exclusion), and full methodological transparency. The definitive reference standard for EV characterization in manufacturing and research contexts.
-
Shelke GV, Lasser C, Gho YS, Lotvall J. Importance of exosome depletion protocols to eliminate functional and RNA-containing extracellular vesicles from fetal bovine serum. Journal of Extracellular Vesicles. 2014;3:24783.
Quantified bovine EV burden in standard FBS preparations at approximately 10^12 particles per mL, and demonstrated that standard ultracentrifugation depletion protocols do not fully remove bovine EVs from FBS. Showed that residual bovine EVs carry biologically active RNA. Foundational paper establishing the FBS EV contamination problem in exosome manufacturing.
Section 3: Passage Number, Replicative Senescence, and SASP
-
Bonab MM, Alimoghaddam K, Talebian F, et al. Aging of mesenchymal stem cell in vitro. BMC Cell Biology. 2006;7:14.
Systematic characterization of MSC aging across serial passages. Documented progressive morphological changes, declining proliferative capacity, telomere shortening (measured by Q-PCR), and p21/CDKN1A upregulation with passage. Established the passage-dependent trajectory of MSC aging and provided quantitative data on the rate of functional decline — directly relevant to harvest-window decisions for exosome production.
-
Wagner W, Horn P, Castoldi M, et al. Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS One. 2008;3(5):e2213.
Transcriptomic analysis of MSC senescence across passages revealed that replicative aging is a continuous, organized process with a defined gene expression signature that begins early in passage history — not an abrupt transition at a specific passage. Showed progressive suppression of differentiation-related and immunomodulatory genes alongside increasing senescence pathway activation. Documented that functional changes precede frank morphological senescence.
-
Turinetto V, Vitale E, Giachino C. Senescence in human mesenchymal stem cells: functional changes and implications in stem cell-based therapy. International Journal of Molecular Sciences. 2016;17(7):1164.
Comprehensive review of MSC senescence mechanisms, markers, and therapeutic consequences. Documented loss of immunomodulatory capacity (reduced IDO, PGE2, IL-10 secretion) and emergence of SASP (elevated IL-6, IL-8, MMP-1, MMP-3) with passage. Reviewed SA-beta-gal, p21, p16, and telomere-length based senescence detection methods. Directly relevant to quality standards for exosome manufacturing from MSC banks.
-
Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nature Reviews Molecular Cell Biology. 2007;8(9):729-740.
Foundational review defining cellular senescence biology including the DNA damage response pathway leading to p53/p21 and p16/Rb activation, and the downstream NF-kB-dependent SASP. Characterizes the stereotyped pro-inflammatory secretory program of senescent cells — including IL-6, IL-8, MMP family members, and GRO-alpha — that constitutes the pathological output of high-passage MSC cultures. Essential background for understanding why passage number matters.
Section 4: Xenofree Manufacturing and FBS Contamination
-
Spees JL, Gregory CA, Singh H, et al. Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Molecular Therapy. 2004;9(5):747-756.
Demonstrated that MSCs cultured in FBS internalize and display bovine proteins on their surface, potentially generating immune recognition. Showed that FBS-cultured MSCs provoke antibody responses to bovine antigens in immunized recipients. Established the mechanism of xenogeneic antigen incorporation and the immunological consequences — foundational rationale for xenofree manufacturing.
-
Bernardo ME, Avanzini MA, Ciccocioppo R, et al. Phenotypical/functional characterization of in vitro-expanded mesenchymal stromal cells from patients with Crohn's disease. Cytotherapy. 2009;11(7):825-836.
Demonstrated equivalent MSC expansion and immunosuppressive function using human platelet lysate (HPL) versus FBS, establishing the feasibility of xenofree MSC expansion without loss of therapeutic function. Contributed to the clinical evidence base supporting xenofree manufacturing adoption for human therapeutic applications.
-
Mendicino M, Bailey AM, Wonnacott K, Puri RK, Bauer SR. MSC-based product characterization for clinical trials: an FDA perspective. Cell Stem Cell. 2014;14(2):141-145.
FDA perspective on MSC product characterization requirements for IND-stage clinical trials. Describes CMC expectations for raw material qualification (including FBS lot testing requirements), manufacturing process consistency, and potency assay requirements. Directly relevant to understanding why xenofree manufacturing simplifies regulatory pathway and why FBS-based manufacturing triggers additional documentation burden.
Section 5: ISCT Criteria, EV Characterization, and Quality Standards
-
Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cell Therapy position statement. Cytotherapy. 2006;8(4):315-317.
The definitive ISCT position statement defining the three minimal criteria for MSC identity adopted as the international standard: plastic adherence, surface marker phenotype (CD73+/CD90+/CD105+; CD45-/CD34-/CD14-/HLA-DR-), and in vitro tri-lineage differentiation potential. The reference standard against which all MSC characterization is measured, and the starting point for understanding why additional functional characterization is necessary.
-
Sipp D, Robey PG, Turner L. Clear up this stem-cell mess. Nature. 2018;561(7724):455-457.
Policy perspective from Nature on the disconnect between the peer-reviewed MSC literature and commercial product claims. Highlighted that passage number, culture conditions, and functional characterization are systematically underreported or misrepresented in commercial MSC products. Argues for mandatory disclosure standards. Relevant context for practitioners evaluating commercial exosome preparations.
-
Lener T, Gimona M, Aigner L, et al. Applying extracellular vesicles based therapeutics in clinical trials — an ISEV position paper. Journal of Extracellular Vesicles. 2015;4:30087.
ISEV position paper on the requirements for translating EV-based therapeutics into clinical trials. Covers manufacturing process documentation, EV characterization standards for clinical-grade preparations, sterility and safety testing requirements, and regulatory considerations across multiple jurisdictions. Directly relevant to the COA standards practitioners should require for any exosome preparation used in clinical settings.
Apply These Standards in Practice
The literature above defines the standard. Find certified practitioners who apply it, or apply for certification yourself.